Walleye Capital
DGX icon

Walleye Capital’s Quest Diagnostics DGX Stock Holding History

Walleye Capital’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$216K Sell
1,100
-18,100
-94% -$3.52M ﹤0.01% 3298
2025
Q4 		$3.33M Buy
19,200
+8,200
+75% +$1.49M 0.01% 1460
2025
Q3 		$2.1M Buy
11,000
+6,200
+129% +$1.1M 0.01% 1538
2025
Q2 		$862K Sell
4,800
-6,900
-59% -$1.2M ﹤0.01% 2166
2025
Q1 		$1.98M Sell
11,700
-800
-6% -$131K 0.01% 1421
2024
Q4 		$1.89M Buy
12,500
+3,900
+45% +$607K ﹤0.01% 1835
2024
Q3 		$1.34M Sell
8,600
-14,700
-63% -$2.2M ﹤0.01% 2342
2024
Q2 		$3.19M Sell
23,300
-21,800
-48% -$2.99M 0.01% 1673
2024
Q1 		$6M Sell
45,100
-7,200
-14% -$934K 0.01% 1167
2023
Q4 		$7.21M Buy
52,300
+31,800
+155% +$4.18M 0.02% 865
2023
Q3 		$2.5M Buy
20,500
+12,000
+141% +$1.6M 0.01% 1560
2023
Q2 		$1.19M Buy
+8,500
New +$1.17M ﹤0.01% 1707
2019
Q4 		– Sell
-100
Closed -$11K – 1890
2019
Q3 		$11K Sell
100
-200
-67% -$20.5K ﹤0.01% 1767
2019
Q2 		$31K Buy
+300
New +$28.8K ﹤0.01% 1463

Other funds holding DGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return

Walleye Capital's DGX Position: Q1 2026 in Review

Walleye Capital reduced its Quest Diagnostics (DGX) stake by 86% in Q1 2026, selling an estimated $2.69M and leaving 2,218 shares worth $435K. The position accounts for ﹤0.01% of the portfolio, ranked #2772.

Walleye Capital first reported a position in DGX in Q2 2019 and has held it in 11 quarters since. The position peaked at $2.79M in Q4 2025. 1,064 funds tracked by Wall St. Rank hold DGX as of Q1 2026.

  • Walleye Capital held 2,218 shares of Quest Diagnostics worth $435K as of Q1 2026.
  • Walleye Capital sold 13,861 Quest Diagnostics shares in Q1 2026, an estimated $2.69M.
  • Quest Diagnostics made up ﹤0.01% of Walleye Capital's portfolio in Q1 2026, its #2772 holding.
  • Walleye Capital first reported a position in Quest Diagnostics in Q2 2019 and has held it in 11 quarters since.
  • Walleye Capital's Quest Diagnostics position peaked at $2.79M in Q4 2025.
  • 1,064 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.